Skip to content

Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy

Non-invasive Assessment to Predict Tolerance to Fluid Removal on Intermittent Kidney Replacement Therapy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05270759
Acronym
TECHNO-HDF
Enrollment
93
Registered
2022-03-08
Start date
2022-03-01
Completion date
2024-09-17
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Chronic Kidney Disease Stage 5 on Dialysis, Chronic Kidney Failure, Fluid Overload, Intradialytic Hypotension

Keywords

Relative blood volume monitoring, Hemodialysis, Hemodiafiltration, Venous Doppler

Brief summary

This prospective cohort study aim to investigate the ability of multiple types of assessments including 1) the modified Venous Excess Ultrasound (VExUS) assessment, 2) non-invasive estimation of absolute blood volume (ABV), and 3) change in carotid Doppler at the start of IKRT to predict IDHE in acutely ill hospitalized patients. The secondary aim will be to determine whether each modality improves the prediction of IHDE compared to the evaluation of the attending physician and whether they also predict cerebral hypoxia during IKRT measured by near-infrared spectroscopy (NIRS). Finally, detailed hemodynamic data including relative blood volume monitoring, tissue oximetry, and other parameters will be collected continuously during IKRT sessions enabling exploratory analyses aimed at identifying hemodynamic phenotypes related to IDHE during IKRT.

Detailed description

Background: Fluid accumulation and intra-dialytic hypotensive events (IDHE) are independently associated with worse prognosis in patients undergoing intermittent kidney replacement therapy (IKRT), both in the setting of acute kidney injury (AKI) and in patients with end-stage kidney disease (ESKD). An optimal IKRT prescription needs to achieve adequate fluid homeostasis while mitigating the risk of IDHE. However, predicting tolerance to fluid removal is challenging, particularly in acutely ill hospitalized patients in whom intravascular volume and compensatory mechanisms are affected by the presence of acute illness. The following modalities will be investigated in this study to determine if they predict IDHE during hemodialysis in hospitalized patients: * The modified VExUS assessment before the hemodialysis session * Estimation of absolute blood volume during the hemodialysis session * Removed in protocol version 2.0: Change in carotid Doppler parameters in response to fluid administration at the start of hemodialysis Objectives: Primary objective: To determine whether the studied modalities accurately predicts intradialytic hypotension events (IDHE) in hospitalized patients, including critically ill and non-critically ill patients Secondary objectives: To determine whether the studied modalities predict cerebral desaturations events measured by near infra-red tissue oximetry (NIRS) during IKRT To determine if adding information from the studied modalities result in significant improvement in the risk prediction of IDHE when added to the subjective assessment of the attending clinician Study design: A cohort of hospitalized patients undergoing hemodiafiltration with ultrafiltration will be monitored during two separate dialysis sessions. The following markers will assessed: 1. Absolute blood volume, estimated based on the change in relative blood volume measured by the Fresenius BVM after infusion of a replacement fluid bolus of 240 mL given 15 minutes after dialysis initiation using the Kron et al method. 2. The modified VExUS from the Doppler assessment of the portal, hepatic, femoral, and splenic vein before the hemodialysis treatment.

Interventions

DIAGNOSTIC_TESTEstimated absolute blood volume

Baseline absolute blood volume will be inferred based on the change in relative blood volume (RBV) after a single 240mL replacement fluid infusion and then monitored throughout the session via the RBV value.

DIAGNOSTIC_TESTModified VExUS evaluation

The presence of at least 2/3 abnormal venous Doppler waveforms at the following sites: Portal vein, hepatic vein, and femoral vein.

Sponsors

The Kidney Foundation of Canada
CollaboratorOTHER
Centre hospitalier de l'Université de Montréal (CHUM)
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Adult patient ≥18 year-old 2. Hospitalized at the CHUM in the intensive care unit (ICU) or general ward 3. Receiving or planned ≥3x/week IKRT treatments 4. Planned on-line hemodiafiltration (HDF) or hemodialysis (HD) sessions with ≥1L of fluid removal per session

Exclusion criteria

1. Planned hospital discharge, death, or transition to comfort care within 48 hours according to the attending physician 2. End of active care (awaiting hospital discharge)

Design outcomes

Primary

MeasureTime frameDescription
Intradialytic hypotensive event in the peri-dialytic or post-dialytic periodFrom the initiation of dialysis to 15 minutes after dialysisIntradialytic hypotension will be defined as a drop in systolic blood pressure below 90 mmHg which requires an intervention (dialysis interruption, vasopressor initiation or dosage increase, fluid bolus, interruption of net ultrafiltration, change in body position with therapeutic intent) In patients with a baseline below 90 mmHg, it will be defined as a decrease of more than 10 mmHg from baseline systolic blood pressure.

Secondary

MeasureTime frameDescription
Intradialytic cerebral desaturation eventsFrom the initiation of dialysis to 15 minutes after dialysis\>15% decrease in cerebral oximetry (NIRS) measurements relative to baseline value.
Rate of intradialytic hypotensionFrom enrolment to 14 daysThe proportion of sessions with at least one episode of intradialytic hypotension (as previously defined) within 14 days from enrollment
Mortality rateFrom enrolment to 90 daysAll cause mortality

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026